๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Sutton
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Sutton

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 2850 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 23 Sep 2026, 03:15 UTC
2850
Studies in scope
industry-sponsored, all four open statuses
1383
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2005 Manchester 672 Birmingham 470 Glasgow 437 Cambridge 417
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to
221 of 2850 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Active, closed
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
NCT05908734Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 1/2
71
London, Newcastle, Sutton
2023-05-18
Active, closed
Study of GS-4528 in Adults With Solid Tumors
NCT05840224Solid Tumor
Gilead Sciences
Phase 1
182
London, Sutton
2023-05-11
Recruiting
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
NCT05800665Advanced Prostate Cancer, Metastatic Prostate Cancer
Genentech, Inc.
Phase 1
210
Cambridge, Leicester, Manchester, Sutton
2023-05-02
Active, closed
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer
NCT05723562Neoplasms, Rectal
GlaxoSmithKline
Phase 2
154
Leeds West Yorkshire, London, Sutton
2023-04-03
Active, closed
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
AbbVie
Phase 3
520
Cheltenham, London, Northwood, Southampton, Sutton, Manchester, Swansea
2023-03-15
Recruiting
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562H3 K27M, Glioma
Jazz Pharmaceuticals
Phase 3
510
Cambridge, Glasgow, Liverpool, Manchester, Sutton, Newcastle upon Tyne, Leeds, London
2023-01-23
Active, closed
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
NCT05608291Melanoma
Regeneron Pharmaceuticals
Phase 3
1,564
Exeter, Edinburgh, Bristol, Sutton, Coventry, London, Manchester, Taunton
2023-01-16
Active, closed
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
NCT05024773Bladder Carcinoma in Situ (CIS)
Fidia Farmaceutici s.p.a.
Phase 3
130
Dartford, Huddersfield, Leeds, London, Plymouth, Preston, Sutton
2022-12-29
Recruiting
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
NCT05549297Advanced Melanoma
Immunocore Ltd
Phase 3
540
Cambridge, Manchester, Birmingham, Leeds, London, Middlesex, Sutton
2022-12-19
Active, closed
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
NCT05488314Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 1/2
57
London, Newcastle upon Tyne, Sutton
2022-12-13
Active, closed
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05501886Breast Cancer
Celcuity Inc
Phase 3
701
Bath, Cardiff, London, Manchester, Nottingham, Sutton
2022-12-08
Recruiting
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
NCT05652335Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC
Phase 1
180
London, Sutton
2022-11-22
Recruiting
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
714
London, Sutton
2022-10-25
Recruiting
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Newcastle upon Tyne, Glasgow, Sutton, Bristol, Cambridge, Leeds, London, Manchester
2022-10-24
Active, closed
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
864
Blackpool, Dundee, London, Newcastle upon Tyne, Nottingham, Plymouth, Sutton, Wolverhampton
2022-10-13
Active, closed
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRฮฑ) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
NCT05456685High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
AbbVie
Phase 2
125
London, Northwood, Nottingham, Taunton, Sutton, Manchester
2022-09-28
Active, closed
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
NCT05371093Relapsed/Refractory Follicular Lymphoma
Kite, A Gilead Company
Phase 3
231
Birmingham, Cambridge, London, Manchester, Oxford, Southampton, Sutton
2022-09-22
Active, closed
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
NCT05450692Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
594
Guildford, Metropolitan Borough of Wirral, Stevenage, Sutton
2022-09-15
Active, closed
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
NCT05425940Colorectal Cancer
Exelixis
Phase 3
901
Bristol, Birmingham, Edinburgh, London, Romford, Sutton
2022-09-07
Active, closed
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
NCT05388669Advanced or Metastatic Non-small Cell Lung Cancer
Janssen Research & Development, LLC
Phase 3
418
Birmingham, London, Newcastle upon Tyne, Sutton
2022-08-05
Recruiting
A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
NCT05463263Lymphoma, B-Cell, Lymphoma, T-Cell
Step Pharma, SAS
Phase 1/2
180
Leicester, London, Manchester, Nottingham, Oxford, Plymouth, Sutton
2022-08-03
Recruiting
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
NCT05384626Locally Advanced Solid Tumor, Metastatic Solid Tumor
Nuvalent Inc.
Phase 1/2
840
Sutton, Edinburgh, London, Manchester
2022-06-09
Recruiting
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
NCT05413421Metastatic Prostate Cancer
ORIC Pharmaceuticals
Phase 1
275
Sutton
2022-06-01
Recruiting
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
NCT05307705Breast Cancer
Eli Lilly and Company
Phase 1
260
London, Sutton
2022-05-11
Active, closed
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
NCT05074810Non Small Cell Lung Cancer, KRAS Activating Mutation
Verastem, Inc.
Phase 1/2
153
Leicester, London, Sutton
2022-04-12
Active, closed
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05348577Prostate Cancer
AstraZeneca
Phase 3
1,035
Edinburgh, Glasgow, Guildford, Hackensack, London, Manchester, Southampton, Sutton
2022-03-25
Active, closed
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT05277051Neoplasms
GlaxoSmithKline
Phase 1
152
Manchester, Sutton
2022-03-22
Active, closed
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05132582HER2 Positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
London, Sutton, Manchester
2022-03-07
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
Sumitomo Pharma America, Inc.
Phase 1/2
606
Birmingham, Bristol, Edinburgh, London, Manchester, Oxford, Stoke-on-Trent, Sutton
2022-02-28
Active, closed
A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
NCT05094336Advanced MTAP-null Solid Tumors
Amgen
Phase 1/2
329
London, Sutton
2022-02-01
Active, closed
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
NCT05163041Advanced Solid Tumor
BicycleTx Limited
Phase 1/2
200
Sutton, Glasgow
2021-11-02
Recruiting
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
NCT04929223Metastatic Colorectal Cancer
Hoffmann-La Roche
Phase 1
542
Cambridge, Cardiff, London, Manchester, Sutton
2021-10-22
Recruiting
A Study of NX-1607 in Adults With Advanced Malignancies
NCT05107674Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
Nurix Therapeutics, Inc.
Phase 1
345
Sutton, Cambridge, Glasgow, London, Manchester, Newcastle, Oxford
2021-09-29
Recruiting
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04910568Multiple Myeloma
Genentech, Inc.
Phase 1
186
London, Sutton
2021-07-26
Active, closed
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
NCT04886804Neoplasm Metastasis, Non-Small Cell Lung Cancer
Boehringer Ingelheim
Phase 1
554
London, Sutton
2021-07-02
Active, closed
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
NCT04689828Prostatic Neoplasms
Novartis Pharmaceuticals
Phase 3
469
Guildford, Sutton, Coventry, London, Middlesbrough
2021-06-15
Active, closed
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
NCT04824092Diffuse Large B-cell Lymphoma
Incyte Corporation
Phase 3
899
Aberdeen, Bath, Birmingham, Bristol, London, Nottingham, Sutton, Wolverhampton
2021-05-11
Active, closed
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
NCT04660344Muscle-invasive Bladder Cancer
Hoffmann-La Roche
Phase 3
761
Cambridge, Edinburgh, London, Plymouth, Preston, Sheffield, Southampton, Sutton
2021-05-03
Active, closed
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
NCT04680052Follicular Lymphoma, Marginal Zone Lymphoma
Incyte Corporation
Phase 3
654
Birmingham, Bristol, Leicester, London, Manchester, Middlesbrough, Sutton, Wolverhampton
2021-04-15
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
Merck Sharp & Dohme LLC
Phase 2
490
Bristol, Nottingham, Windsor, London, Oxford, Newmarket, Sutton, Manchester
2021-04-05
Active, closed
Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
NCT04675294Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
ALX Oncology Inc.
Phase 2
189
London, Sutton
2021-04-02
Active, closed
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
NCT04647526Metastatic Castration-Resistant Prostate Cancer
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Phase 3
455
London, Sutton
2021-02-25
Active, closed
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
NCT04628494Diffuse Large B-cell Lymphoma
Genmab
Phase 3
483
Birmingham, London, Norwich, Nottingham, Plymouth, Southampton, Sutton, Truro
2021-01-13
Active, closed
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
NCT04579380Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
217
London, Sutton
2021-01-11
Active, closed
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
NCT04634877Endometrial Neoplasms
Merck Sharp & Dohme LLC
Phase 3
990
Bristol, Cottingham, Glasgow, London, Sutton, Leicester, Manchester
2021-01-10
Active, closed
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
NCT04607421Neoplasms
Pfizer
Phase 3
841
Newcastle upon Tyne, Sutton, Birmingham, London, Oxford
2020-12-21
Active, closed
A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
NCT04625270Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
Verastem, Inc.
Phase 2
225
Edinburgh, Glasgow, London, Manchester, Sutton
2020-12-21
Active, closed
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT04644068Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
AstraZeneca
Phase 1/2
702
Cambridge, Manchester, Oxford, Sutton
2020-11-12
Active, closed
A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies
NCT04606381Neoplasms
Janssen Research & Development, LLC
Phase 1
158
Manchester, Sutton
2020-11-10
Active, closed
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
NCT04546009Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche
Phase 3
992
Brighton, Leicester, London, Maidstone, Peterborough, Plymouth, Sutton, Truro
2020-10-09
Active, closed
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
NCT04590963Squamous Cell Carcinoma of the Head and Neck
AstraZeneca
Phase 3
370
London, Manchester, Newcastle upon Tyne, Sutton
2020-10-02
Active, closed
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT04484623Multiple Myeloma
GlaxoSmithKline
Phase 3
302
London, Plymouth, Southampton, Stoke-on-Trent, Sutton
2020-10-01
Active, closed
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04487080Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 3
1,074
Edinburgh, London, Manchester, Nottingham, Sutton
2020-09-30
Active, closed
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04557098Hematological Malignancies
Janssen Research & Development, LLC
Phase 2
194
London, Sothampton, Sutton
2020-09-17
Active, closed
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT04384484Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
ADC Therapeutics S.A.
Phase 3
440
Sutton, Glasgow, Manchester
2020-09-16
Active, closed
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
AstraZeneca
Phase 2
477
London, Manchester, Sutton
2020-08-18
Active, closed
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
NCT04493853Hormone-Sensitive Prostate Cancer
AstraZeneca
Phase 3
1,012
Cambridge, Guildford, Manchester, Plymouth, Sutton, Whitchurch
2020-07-13
Recruiting
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
1,006
Sutton, Birmingham, London
2020-06-08
Active, closed
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
NCT04379596Gastric Cancer
AstraZeneca
Phase 2
452
Cambridge, Dundee, London, Manchester, Sutton
2020-06-03
Active, closed
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
NCT04305496Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca
Phase 3
818
Aberdeen, Bournemouth, Bristol, Cardiff, Cheltenham, London, Manchester, Sutton
2020-04-16
Active, closed
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
NCT04288089Receptors, Estrogen, Genes, Erbb-2, Breast Neoplasms
Eisai Inc.
Phase 1
31
London, Sutton
2020-04-01
Active, closed
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
NCT04195750Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 3
755
Cambridge, Edinburgh, Glasgow, London, Sutton, Gillingham, Manchester
2020-02-27
Active, closed
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
NCT04042701Breast Cancer, Non-small Cell Lung Carcinoma
Daiichi Sankyo
Phase 1
115
London, Manchester, Sutton
2020-02-10
Recruiting
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
NCT03934372Acute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blast Phase Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia
Incyte Biosciences International Sร rl
Phase 1/2
70
Glasgow, Liverpool, Sutton
2020-01-29
Active, closed
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
NCT04129502Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Takeda
Phase 3
354
London, Sutton, Bebington, Leicester, Manchester
2020-01-10
Active, closed
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
NCT04170153Metastatic or Locally Advanced Unresectable Solid Tumors
EMD Serono Research & Development Institute, Inc.
Phase 1
161
Cambridge, Manchester, Newcastle upon Tyne, Sutton
2019-12-20
Active, closed
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
NCT03888105B-cell Non-Hodgkin Lymphoma (B-NHL)
Regeneron Pharmaceuticals
Phase 2
515
Truro, Plymouth, Sutton, Cardiff, London
2019-11-13
Active, closed
Pediatric Long-Term Follow-up and Rollover Study
NCT03975829Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood
Novartis Pharmaceuticals
Phase 4
163
Sutton, Liverpool, London
2019-11-04
Active, closed
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
NCT03975647HER2-positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
Truro, Edinburgh, Birmingham, London, Manchester, Sutton
2019-10-02
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
Novartis Pharmaceuticals
Phase 1/2
300
Bath, Leicester, London, Manchester, Oxford, Southampton, Sutton, Taunton
2019-09-18
Active, closed
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
NCT04083599Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma
Genmab
Phase 1/2
350
Sutton
2019-09-17
Active, closed
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
NCT04002297Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
BeOne Medicines
Phase 3
510
Abergavenny, Birmingham, Dudley, Sutton
2019-08-20
Recruiting
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
NCT04068597Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma
CellCentric Ltd.
Phase 1/2
250
Sutton, Bebington, Bristol, Cardiff, Derby, Edinburgh, Glasgow, Leicester
2019-08-09
Active, closed
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
NCT03767244Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 3
2,517
Bristol, Cardiff, Dundee, London, Preston, Sutton, Wakefield, Wolverhampton
2019-06-11
Active, closed
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
NCT03845166Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
Exelixis
Phase 1
325
London, Sutton, Preston
2019-03-20
Active, closed
Durvalumab and Tremelimumab for Pediatric Malignancies
NCT03837899Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
AstraZeneca
Phase 1/2
50
Leeds, London, Sutton
2019-03-07
Recruiting
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
NCT03761108Multiple Myeloma
Regeneron Pharmaceuticals
Phase 1/2
387
Sutton
2019-01-23
Active, closed
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
NCT03701334Early Breast Cancer
Novartis Pharmaceuticals
Phase 3
5,101
Truro, Sutton, Cardiff, London, Nottingham, Oxford, Preston, Stoke-on-Trent
2018-12-07
Active, closed
Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.
NCT03616587ER+ HER2- Advanced Breast Cancer
AstraZeneca
Phase 1
396
Cambridge, Leeds, London, Manchester, Sutton
2018-10-11
Active, closed
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
NCT03602859Ovarian Neoplasms, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Tesaro, Inc.
Phase 3
1,400
Glasgow, Metropolitan Borough of Wirral, Portsmouth, Sutton, Truro
2018-10-11
Active, closed
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
NCT03553836Melanoma
Merck Sharp & Dohme LLC
Phase 3
976
Cambridge, London, Sutton, Manchester
2018-09-12
Active, closed
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
NCT03625037DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL
Genmab
Phase 1/2
666
Manchester, Plymouth, Southampton, Sutton
2018-06-26
Active, closed
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
NCT03485209Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
350
London, Sutton
2018-06-25
Active, closed
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.
Phase 3
565
Aberdeen, London, Sutton, Cambridge, Coventry, Dundee, Leeds, Manchester
2018-06-21
Recruiting
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
NCT03564340Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer
Regeneron Pharmaceuticals
Phase 1/2
890
Oxford, Sutton, London, Manchester
2018-05-21
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
NCT03425643Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
797
Leicester, Metropolitan Borough of Wirral, London, Sutton, Nottingham, Birmingham, Newcastle upon Tyne, Plymouth
2018-04-24
By invitation
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
NCT03391778Neoplasms
USWM CT, LLC
Phase 1
250
London, Manchester, Sutton
2018-04-09
Active, closed
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
NCT03390504Urothelial Cancer
Janssen Research & Development, LLC
Phase 3
629
Bristol, London, Manchester, Plymouth, Sheffield, Southampton, Sutton
2018-03-23
Active, closed
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT03431350Prostatic Neoplasms, Castration-Resistant
Janssen Research & Development, LLC
Phase 2
136
Bath, London, Southampton, Sutton, Truro
2018-03-02
Active, closed
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
NCT03313778Solid Tumors
ModernaTX, Inc.
Phase 1
161
Dundee, Sutton, London
2017-08-14
Rows per page Showing 101–200 of 221
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-uk/city/sutton?page=2

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.